CCL3 and diabetes mellitus: When analyzing the expression of the same molecules in neutrophils from ACS patients with diabetes compared to non-diabetic individuals, regardless of their prognosis, the results revealed no significant differences in the gene expression levels of pro-inflammatory molecules CCL3, IL-1β, IL-18, IL-6, S100A9, ICAM-1 (Figure 5A–G), data in agreement with clinical evaluation (Figure 5D–F).